Ascendis Pharma A (ASND) Accounts Payables (2012 - 2026)
Ascendis Pharma A (ASND) posted Accounts Payables of $92.0 million for Q1 2026, down 12.81% sequentially from $105.5 million in Q4 2025, and up 3.67% YoY from $88.7 million in Q1 2025.
Ascendis Pharma A (ASND) Accounts Payables (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Accounts Payables for 15 years, with the latest figure at $92.0 million in Q1 2026.
- Quarterly Accounts Payables rose 3.67% year-over-year to $92.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.0 million (up 3.67% YoY) and the FY2025 annual result came in at $105.5 million, up 2.45% from the prior year.
- Accounts Payables retreated to $92.0 million in Q1 2026 per ASND's latest filing, from $105.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $141.1 million in Q1 2023 and troughed at $79.3 million in Q1 2022.
- A 5-year average of $102.2 million and a median of $102.7 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables soared 77.84% in 2023, then slumped 37.53% in 2024.
- Over 5 years, Accounts Payables stood at $103.1 million in 2022, then retreated by 1.29% to $101.7 million in 2023, then gained by 1.24% to $103.0 million in 2024, then advanced by 2.45% to $105.5 million in 2025, then decreased by 12.81% to $92.0 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $92.0 million, $105.5 million, and $91.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 92.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.01 Mn |
| Dec 31, 2025 | 105.53 Mn |
| Sep 30, 2025 | 91.89 Mn |
| Jun 30, 2025 | 106.08 Mn |
| Mar 31, 2025 | 88.75 Mn |
| Dec 31, 2024 | 103.01 Mn |
| Sep 30, 2024 | 82.66 Mn |
| Jun 30, 2024 | 107.18 Mn |
| Mar 31, 2024 | 102.69 Mn |
| Dec 31, 2023 | 101.75 Mn |
| Sep 30, 2023 | 132.32 Mn |
| Jun 30, 2023 | 132.98 Mn |
| Mar 31, 2023 | 141.08 Mn |
| Dec 31, 2022 | 103.08 Mn |
| Sep 30, 2022 | 86.81 Mn |
| Jun 30, 2022 | 80.01 Mn |
| Mar 31, 2022 | 79.33 Mn |
| Dec 31, 2021 | 67.97 Mn |
| Sep 30, 2021 | 90.18 Mn |
| Jun 30, 2021 | 53.24 Mn |